Neumora Therapeutics (NMRA) CFO awarded 350,000-share stock option grant

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. reported that its Chief Financial Officer and Principal Accounting Officer, Michael Lee Milligan, received a grant of a stock option covering 350,000 shares of common stock on January 8, 2026. The option has an exercise price of $2.33 per share and is held directly. According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested and exercisable on the fourth anniversary of that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milligan Michael Lee

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL WAY, SUITE 1

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.33	01/08/2026		A		350,000		(1)	01/08/2036	Common Stock	350,000	$0	350,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: Chief Financial Officer & Principal Accounting Officer

	/s/ Michael Lee Milligan	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Neumora Therapeutics (NMRA) report for January 8, 2026?

Neumora Therapeutics reported that its Chief Financial Officer and Principal Accounting Officer, Michael Lee Milligan, received a grant of a stock option for 350,000 shares of common stock on January 8, 2026.

What are the key terms of Michael Lee Milligan’s stock option at Neumora Therapeutics (NMRA)?

The stock option covers 350,000 shares of Neumora Therapeutics common stock with an exercise price of $2.33 per share and is held directly by Michael Lee Milligan.

How does the 350,000-share stock option for Neumora Therapeutics’ CFO vest?

For this option, 25% of the shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments so that 100% are vested and exercisable on the fourth anniversary of that date.

What position does the reporting person hold at Neumora Therapeutics (NMRA)?

The reporting person, Michael Lee Milligan, serves as Neumora Therapeutics’ Chief Financial Officer and Principal Accounting Officer.

Is the reported Neumora Therapeutics (NMRA) insider transaction a purchase or an award?

The filing shows a stock option grant reported with transaction code A, indicating an award or grant of 350,000 derivative securities, not a market purchase or sale.

How many derivative securities does Neumora’s CFO hold after this option grant?

Following the reported transaction, Michael Lee Milligan beneficially owns 350,000 derivative securities in the form of this stock option.